CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Revolution Medicines Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Revolution Medicines Inc
700 Saginaw Dr
Phone: (650) 481-6801p:650 481-6801 REDWOOD CITY, CA  94063  United States Ticker: RVMDRVMD
Business Summary
Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Mark A.Goldsmith 64 11/1/2014
Chief Financial Officer Jack L.Anders 49 9/1/2022
President - Research and Development Stephen M.Kelsey 65 3/1/2017 3/1/2017
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
EQRx Inc 50 Hampshire Street CAMBRIDGE MA United States

Business Names
Business Name
((REVOLUTION MEDICINES
EQRx Inc
EQRx, LLC
7 additional Business Names available in full report.

General Information
Number of Employees: 883 (As of 12/31/2025)
Outstanding Shares: 212,596,462 (As of 5/1/2026)
Shareholders: 46
Stock Exchange: NASD
Federal Tax Id: 472029180
Fax Number: (302) 636-5454
Email Address: inquiries@revolutionmedicines.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, June 3, 2026